Zaprinast activates MAPKs, NFκB, and Akt and induces the expressions of inflammatory genes in microglia

International Immunopharmacology

Volumn 13, Issue 3, 2012, Pages 232-241

  Lee, Heung Soon ^a   Kwon, Soon Ho ^a   Ham, Ji Eun ^a   Lee, Joo Young ^a   Kim, Dong Hoon ^a   Shin, Kyung Ho ^a   Choi, Sang Hyun ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Lipopolysaccharide; MAPKs; Microglia; NF B; Zaprinast

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CD14 ANTIGEN; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CYCLOOXYGENASE 2; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; ZAPRINAST;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; IN VITRO STUDY; MICROGLIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BASE SEQUENCE; CELLS, CULTURED; CYTOKINES; DNA PRIMERS; GENE EXPRESSION; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MAP KINASE SIGNALING SYSTEM; MICROGLIA; NF-KAPPA B; PHOSPHODIESTERASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PURINONES; RATS; RNA, MESSENGER;

EID: 84861441601     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2012.04.013     Document Type: Article

References (60)

1. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-8. (Pubitemid 26349059)
2. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007;10:1387-94. (Pubitemid 350014685)
3. Aloisi F. Immune function of microglia. Glia 2001;36:165-79. (Pubitemid 33055905)
4. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005;308:1314-8. (Pubitemid 40746128)
5. Gehrmann J, Matsumoto Y, Kreutzberg GW. Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 1995;20:269-87.
6. Garden GA, Moller T. Microglia biology in health and disease. J Neuroimmune Pharmacol Off J Soc Neuroimmune Pharmacol 2006;1:127-37. (Pubitemid 44257488)
7. Rock RB, Peterson PK. Microglia as a pharmacological target in infectious and inflammatory diseases of the brain. J Neuroimmune Pharmacol Off J Soc Neuroimmune Pharmacol 2006;1:117-26. (Pubitemid 44257487)
8. Kim SH, Smith CJ, Van Eldik LJ. Importance of MAPK pathways for microglial proinflammatory cytokine IL-1 beta production. Neurobiol Aging 2004;25:431-9. (Pubitemid 38317340)
9. Zhang Y, Dong C. Regulatory mechanisms of mitogen-activated kinase signaling. Cell Mol Life Sci 2007;64:2771-89. (Pubitemid 351152255)
10. Koistinaho M, Koistinaho J. Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia 2002;40:175-83. (Pubitemid 35337375)
11. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004;4:372-7. (Pubitemid 38987064)
12. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 2005;1754:253-62.
13. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2:717-26. (Pubitemid 37361787)
14. Waetzig V, Czeloth K, Hidding U, Mielke K, Kanzow M, Brecht S, et al. c-Jun Nterminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Glia 2005;50:235-46. (Pubitemid 40769853)
15. Kim WK, Hwang SY, Oh ES, Piao HZ, Kim KW, Han IO. TGF-beta1 represses activation and resultant death of microglia via inhibition of phosphatidylinositol 3- kinase activity. J Immunol 2004;172:7015-23. (Pubitemid 38669143)
16. Jhun BS, JinQ, Oh YT, KimSS, Kong Y, Cho YH, et al. 5-Aminoimidazole-4- carboxamide riboside suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of phosphatidylinositol 3-kinase/Akt activation in RAW 264.7 murine macrophages. Biochem Biophys Res Commun 2004;318:372-80. (Pubitemid 38553790)
17. Hwang SY, Jung JS, Lim SJ, Kim JY, Kim TH, Cho KH, et al. LY294002 inhibits interferon-gamma-stimulated inducible nitric oxide synthase expression in BV2 microglial cells. Biochem Biophys Res Commun 2004;318:691-7.
18. Jang BC, Paik JH, Kim SP, Shin DH, Song DK, Park JG, et al. Catalase induced expression of inflammatory mediators via activation of NF-kappaB, PI3K/AKT, p70S6K, and JNKs in BV2 microglia. Cell Signal 2005;17:625-33.
19. Lee JY, Jhun BS, Oh YT, Lee JH, Choe W, Baik HH, et al. Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of PI 3-kinase/Akt and NF-kappaB activation in murine BV2 microglial cells. Neurosci Lett 2006;396:1-6. (Pubitemid 43233777)
20. Gibson A. Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil. Eur J Pharmacol 2001;411:1-10. (Pubitemid 32013105)
21. Choi SH, Choi DH, Song KS, Shin KH, Chun BG. Zaprinast, an inhibitor of cGMPselective phosphodiesterases, enhances the secretion of TNF-alpha and IL-1beta and the expression of iNOS and MHC class II molecules in rat microglial cells. J Neurosci Res 2002;67:411-21.
22. Bhat NR, Zhang P, Lee JC, Hogan EL. Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures. J Neuroimmune Pharmacol Off J SocNeuroimmune Pharmacol 1998;18:1633-41. (Pubitemid 28103071)
23. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001;13:85-94. (Pubitemid 32222977)
24. Pawate S, Shen Q, Fan F, Bhat NR. Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma. J Neurosci Res 2004;77:540-51. (Pubitemid 39007006)
25. Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006;210:171-86.
26. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994;12:141-79.
27. Baldwin Jr AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83. (Pubitemid 26130197)
28. O'Neill LA, Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 1997;20:252-8. (Pubitemid 27261456)
29. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-66.
30. Zhao Q, Lee FS. Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-kappaB through IkappaB kinase-alpha and IkappaB kinasebeta. J Biol Chem 1999;274:8355-8. (Pubitemid 29164619)
31. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401:82-5.
32. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin Jr AS, Mayo MW. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 2000;20:1626-38. (Pubitemid 30100182)
33. Madrid LV, Mayo MW, Reuther JY, Baldwin Jr AS. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 2001;276:18934-40.
34. Kao TK,Ou YC, Lin SY, PanHC, Song PJ, Raung SL, et al. Luteolin inhibits cytokine expression in endotoxin/cytokine-stimulated microglia. J Nutr Biochem 2011;22:612-24.
35. Lin HY, Tang CH, Chen YH, Wei IH, Chen JH, Lai CH, et al. Peptidoglycan enhances proinflammatory cytokine expression through the TLR2 receptor, MyD88, phosphatidylinositol 3-kinase/AKT and NF-kappaB pathways in BV-2 microglia. Int Immunopharmacol 2010;10:883-91.
36. Li Y, Liu L, Barger SW, Mrak RE, Griffin WS. Vitamin E suppression of microglial activation is neuroprotective. J Neurosci Res 2001;66:163-70. (Pubitemid 32912285)
37. Molnar-Kimber KL, Yonno L, Heaslip RJ, Weichman BM. Differential regulation of TNF-alpha and IL-1beta production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors. Mediators Inflamm 1992;1:411-7.
38. Molnar-Kimber K, Yonno L, Heaslip R, Weichman B. Modulation of TNF alpha and IL-1 beta fromendotoxin-stimulatedmonocytes by selective PDE isozyme inhibitors. Agents Actions 1993;39 [Spec No:C77-9].
39. Klegeris A, McGeer PL. Interaction of various intracellular signaling mechanisms involved in mononuclear phagocyte toxicity toward neuronal cells. J Leukoc Biol 2000;67:127-33. (Pubitemid 30046827)
40. Pifarre P, Prado J, Giralt M, Molinero A, Hidalgo J, Garcia A. Cyclic GMP phosphodiesterase inhibition alters the glial inflammatory response, reduces oxidative stress and cell death and increases angiogenesis following focal brain injury. J Neurochem 2010;112:807-17.
41. El-Mowafy AM, Alkhalaf M, Nassar NN. Resveratrol reverses ET-1-evoked mitogenic effects in human coronary arterial cells by activating the kinase-G to inhibit ERK-enzymes. Int J Cardiol 2009;136:263-9.
42. Bauer PM, Buga GM, Ignarro LJ. Role of p42/p44 mitogen-activated-protein kinase and p21waf1/cip1 in the regulation of vascular smooth muscle cell proliferation by nitric oxide. Proc Natl Acad Sci U S A 2001;98:12802-7. (Pubitemid 33020025)
43. Ho AK, Hashimoto K, Chik CL. 3′,5′-cyclic guanosine monophosphate activates mitogen-activated protein kinase in rat pinealocytes. J Neurochem1999;73:598-604. (Pubitemid 29339832)
44. Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. II. Evidence for the involvement of an inhibitory-kappaB/nuclear factor-kappaBsensitive pathway in alveolar epithelial cells. J Pharmacol Exp Ther 2002;300:567-76. (Pubitemid 34106249)
45. Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther 2002;300:559-66.
46. Fuhrmann M, Jahn HU, Seybold J, Neurohr C, Barnes PJ, Hippenstiel S, et al. Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells. Am J Respir Cell Mol Biol 1999;20:292-302. (Pubitemid 129504890)
47. Wu BN, Chen CW, Liou SF, Yeh JL, Chung HH, Chen IJ. Inhibition of proinflammatory tumor necrosis factor-{alpha}-induced inducible nitric-oxide synthase by xanthinebased 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3- dimethylxanthine (KMUP-1) and 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1,3- dimethylxanthine (KMUP-3) in rat trachea: the involvement of soluble guanylate cyclase and protein kinase G. Mol Pharmacol 2006;70:977-85.
48. Tsai BM,WangM, Pitcher JM, Kher A, Crisostomo P,MeldrumDR. Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone. Shock 2005;24:417-20. (Pubitemid 41567352)
49. Perry MJ, Higgs GA. Chemotherapeutic potential of phosphodiesterase inhibitors. Curr Opin Chem Biol 1998;2:472-81. (Pubitemid 128645700)
50. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999;274:13729-32.
51. Essayan DM. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol 1999;57:965-73. (Pubitemid 29168544)
52. Kaminska B, Gozdz A, Zawadzka M, Ellert-Miklaszewska A, Lipko M. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat Rec (Hoboken) 2009;292:1902-13.
53. Fietta AM, Morosini M, Meloni F, Bianco AM, Pozzi E. Pharmacological analysis of signal transduction pathways required for mycobacterium tuberculosis-induced IL-8 and MCP-1 production in human peripheral monocytes. Cytokine 2002;19: 242-9. (Pubitemid 35257824)
54. Bhat NR, Fan F. Adenovirus infection induces microglial activation: involvement of mitogen-activated protein kinase pathways. Brain Res 2002;948:93-101. (Pubitemid 35283765)
55. Dicou E, Vincent JP,Mazella J. Neurotensin receptor-3/sortilinmediates neurotensininduced cytokine/chemokine expression in a murine microglial cell line. J Neurosci Res 2004;78:92-9. (Pubitemid 39305158)
56. Ito S, Sawada M, HanedaM, Ishida Y, Isobe K. Amyloid-beta peptides induce several chemokine mRNA expressions in the primary microglia and Ra2 cell line via the PI3K/Akt and/or ERK pathway. Neurosci Res 2006;56:294-9. (Pubitemid 44574518)
57. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 2001;98:13681-6. (Pubitemid 33115958)
58. Zhou Y, Ling EA, Dheen ST. Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. J Neurochem 2007;102:667-78. (Pubitemid 47057277)
59. Li M, Wu ZM, Yang H, Huang SJ. NFkappaB and JNK/MAPK activation mediates the production of major macrophage- or dendritic cell-recruiting chemokine in human first trimester decidual cells in response to proinflammatory stimuli. J Clin Endocrinol Metab 2011;96:2502-11.
60. Tseng PC, Hsu HC, Janmanchi D, Lin CH, Kuo YH, Chou CK, et al. Helioxanthin inhibits interleukin-1 beta-induced MIP-1 beta production by reduction of c-jun expression and binding of the c-jun/CREB1 complex to the AP-1/CRE site of the MIP-1 beta promoter in Huh7 cells. Biochem Pharmacol 2008;76:1121-33.